LORINASE SYRUP 100ML

Indications

Approved Uses

Symptomatic relief of allergic rhinitis (seasonal and/or perennial) when accompanied by nasal congestion (e.g., sneezing, rhinorrhea, nasal itching, itchy/watery eyes, and nasal congestion).

Dosage & Administration

Dose Adjustment Notes

Use caution in renal impairment and consider reducing dosing frequency (e.g., once daily) in severe renal impairment; use caution in hepatic impairment (loratadine exposure may increase) and consider longer dosing interval; use caution in older adults and in cardiovascular disease/hypertension due to pseudoephedrine.

Side Effects

Common Side Effects

Headache, insomnia, dry mouth, nervousness, dizziness, palpitations, tachycardia, nausea, fatigue

Safety & Warnings

Contraindications

Hypersensitivity to loratadine or pseudoephedrine, severe hypertension, severe coronary artery disease, use of MAO inhibitors within 14 days, narrow-angle glaucoma, urinary retention, hyperthyroidism

Warnings & Precautions

Use with caution/avoid in uncontrolled hypertension, significant cardiovascular disease/arrhythmias, hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy/urinary retention; avoid with MAOIs (within 14 days); may cause insomnia/nervousness and raise BP/HR; do not exceed recommended dose.

Age Restriction

Not recommended for children under 2 years of age.

Drug Interactions

Drug Interactions

MAO inhibitors (contraindicated/avoid within 14 days), other sympathomimetics/stimulants, tricyclic antidepressants, antihypertensives (may reduce effect), beta-blockers (may increase BP/alter response), ergot alkaloids (additive vasoconstriction), and digoxin/cardiac glycosides (arrhythmia risk with sympathomimetics); CYP3A4 inhibitors (e.g., ketoconazole/erythromycin) can increase loratadine exposure but is usually not clinically significant.

Interaction Severity

MAJOR: MAO inhibitors (and within 14 days of stopping) - risk of hypertensive crisis. MODERATE: Other sympathomimetics/stimulants (additive BP/HR/CNS effects), tricyclic antidepressants (enhanced pressor effects), antihypertensives (may blunt antihypertensive effect), beta-blockers (possible BP effects), digoxin/digitalis (arrhythmia risk with sympathomimetics). MINOR: Strong CYP3A4/2D6 inhibitors (e.g., ketoconazole, macrolides) may increase loratadine/desloratadine exposure but usually limited clinical impact.

Special Populations

Kidney Impairment

CrCl <30 mL/min: use a lower starting dose and/or extend dosing interval (e.g., once daily); use with caution.

Storage & Patient Advice

Monitoring Requirements

No routine monitoring for short-term OTC use in healthy patients; monitor blood pressure and heart rate in patients with hypertension, cardiovascular disease, hyperthyroidism, or those experiencing palpitations/insomnia.

Pharmacology

Mechanism of Action

Loratadine selectively antagonizes peripheral H1 receptors to reduce histamine-mediated allergic symptoms; pseudoephedrine is a sympathomimetic that stimulates alpha-adrenergic receptors causing vasoconstriction in nasal mucosa, reducing edema and congestion.

Onset of Action

1-3 hours.

Duration of Effect

Approximately 12 hours.

Bioavailability

Loratadine: oral bioavailability is variable due to first-pass metabolism (commonly cited ~40%); pseudoephedrine: high oral bioavailability (commonly cited ~90% or higher) with predominant renal elimination.

Metabolism

Loratadine: extensive hepatic first-pass metabolism mainly via CYP3A4 and CYP2D6 to active metabolite (desloratadine/descarboethoxyloratadine). Pseudoephedrine: minimal metabolism; mostly excreted unchanged (minor hepatic metabolism may occur).

Excretion

Loratadine: eliminated as metabolites via both urine and feces (roughly similar proportions, ~40% each over several days). Pseudoephedrine: primarily renal excretion, largely unchanged (about 55-75% unchanged), with urinary pH affecting clearance.

Product Information

Available Dosage Forms

Syrup (oral), 100 mL bottle.

OTC Alternatives

For allergy without congestion: loratadine alone or cetirizine/levocetirizine/fexofenadine. For congestion: short-term topical nasal decongestant (e.g., xylometazoline/oxymetazoline) or intranasal corticosteroid (e.g., fluticasone) if allergic rhinitis predominates.

Symptom Target

Congestion, Runny Nose, Allergy, Multi-symptom

Sedating

No

Reviewed by Al Mujtama Pharmacy Medical Review Team. Last reviewed 30-08-2026